Genetic vaccination for re-establishing T-cell tolerance in type 1 diabetes

References

• Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005; 23:447 - 485
   PubMed Web of Science ®Google Scholar
• Bach JF. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr Rev 1994; 15:516 - 542
   PubMed Web of Science ®Google Scholar
• Eisenbarth GS. Prediction of type 1 diabetes: the natural history of the prediabetic period. Adv Exp Med Biol 2004; 552:268 - 290
   PubMed Web of Science ®Google Scholar
• Tisch R, McDevitt HO. Insulin-dependent diabetes mellitus. Cell 1996; 85:291 - 297
   PubMed Web of Science ®Google Scholar
• Bendelac A, Carnaud C, Boitard C, Bach JF. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells. J Exp Med 1987; 166:823 - 832
   PubMed Web of Science ®Google Scholar
• Christianson SW, Shultz LD, Leiter EH. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors. Diabetes 1993; 42:44 - 55
   PubMed Web of Science ®Google Scholar
• Miller BJ, Appel MC, O'Neil JJ, Wicker LS. Both the Lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in nonobese diabetic mice. J Immunol 1988; 140:52 - 58
   PubMed Web of Science ®Google Scholar
• Standifer NE, Burwell EA, Gersuk VH, Greenbaum CJ, Nepom GT. Changes in autoreactive T cell avidity during type 1 diabetes development. Clin Immunol 2009; 132:312 - 320
   PubMed Web of Science ®Google Scholar
• Velthuis JH, Unger WW, Abreu JR, Duinkerken G, Franken K, Peakman M, et al. Simultaneous detection of circulating autoreactive CD8+ T cells specific for different islet cell-associated epitopes using combinatorial MHC-multimers. Diabetes 2010; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Coppieters KT, von Herrath MG. Histopathology of type 1 diabetes: old paradigms and new insights. Rev Diabet Stud 2009; 6:85 - 96
   PubMedGoogle Scholar
• Arif S, Tree TI, Astill TP, Tremble JM, Bishop AJ, Dayan CM, et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004; 113:451 - 463
   PubMed Web of Science ®Google Scholar
• Todd JA, Wicker LS. Genetic protection from the inflammatory disease type 1 diabetes in humans and animal models. Immunity 2001; 15:387 - 395
   PubMed Web of Science ®Google Scholar
• Sarvetnick N. Etiology of autoimmunity. Immunol Res 2000; 21:357 - 362
   PubMed Web of Science ®Google Scholar
• Benoist C, Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry?. Nat Immunol 2001; 2:797 - 801
   PubMed Web of Science ®Google Scholar
• Tisch R, Wang B. Dysregulation of T peripheral tolerance in type 1 diabetes. Adv Immunol 2008; 100:125 - 149
   PubMed Web of Science ®Google Scholar
• Brusko TM, Wasserfall CH, Clare-Salzler MJ, Schatz DA, Atkinson MA. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 2005; 54:1407 - 1414
   PubMed Web of Science ®Google Scholar
• Fox CJ, Danska JS. IL-4 expression at the onset of islet inflammation predicts nondestructive insulitis in nonobese diabetic mice. J Immunol 1997; 158:2414 - 2424
   PubMed Web of Science ®Google Scholar
• Gregori S, Giarratana N, Smiroldo S, Adorini L. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol 2003; 171:4040 - 4047
   PubMed Web of Science ®Google Scholar
• Herman AE, Freeman GJ, Mathis D, Benoist C. CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion. J Exp Med 2004; 199:1479 - 1489
   PubMed Web of Science ®Google Scholar
• Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TI. Defective suppressor function in CD4+CD25+ T-cells from patients with type 1 diabetes. Diabetes 2005; 54:92 - 99
   PubMed Web of Science ®Google Scholar
• Pop SM, Wong CP, Culton DA, Clarke SH, Tisch R. Single cell analysis shows decreasing FoxP3 and TGFbeta1 coexpressing CD4+CD25+ regulatory T cells during autoimmune diabetes. J Exp Med 2005; 201:1333 - 1346
   PubMed Web of Science ®Google Scholar
• Shevach EM. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006; 25:195 - 201
   PubMed Web of Science ®Google Scholar
• Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346:1692 - 1698
   PubMed Web of Science ®Google Scholar
• Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352:2598 - 2608
   PubMed Web of Science ®Google Scholar
• Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005; 54:1763 - 1769
   PubMed Web of Science ®Google Scholar
• Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GS, Robinson P, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993; 366:69 - 72
   PubMed Web of Science ®Google Scholar
• Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, McDevitt HO. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993; 366:72 - 75
   PubMed Web of Science ®Google Scholar
• Tisch R, Liblau RS, Yang XD, Liblau P, McDevitt HO. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 1998; 47:894 - 899
   PubMed Web of Science ®Google Scholar
• Fife BT, Guleria I, Gubbels-Bupp M, Eagar TN, Tang Q, Bour-Jordan H, et al. Insulin-induced remission in new onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med 2006; 203:2737 - 2747
   PubMed Web of Science ®Google Scholar
• Muir A, Peck A, Clare-Salzler M, Song YH, Cornelius J, Luchetta R, et al. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription. J Clin Invest 1995; 95:628 - 634
   PubMed Web of Science ®Google Scholar
• Coon B, An LL, Whitton JL, von Herrath MG. DNA immunization to prevent autoimmune diabetes. J Clin Invest 1999; 104:189 - 194
   PubMed Web of Science ®Google Scholar
• Harrison LC, Honeyman MC, Steele CE, Stone NL, Sarugeri E, Bonifacio E, et al. Pancreatic beta cell function and immune response to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 2004; 27:2348 - 2355
   PubMed Web of Science ®Google Scholar
• Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 2005; 28:1068 - 1076
   PubMed Web of Science ®Google Scholar
• Orban T, Farkas K, Jalahej H, Kis J, Treszl A, Falk B, et al. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 2010; 34:408 - 415
   PubMed Web of Science ®Google Scholar
• Ludvigsson J, Faresjo M, Hjorth M, Axelsson S, Cheramy M, Pihl M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008; 359:1909 - 1920
   PubMed Web of Science ®Google Scholar
• Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Eng J Med 2002; 346:1685 - 1691
   PubMed Web of Science ®Google Scholar
• Liblau RS, Pearson CI, Shokat K, Tisch R, Yang XD, McDevitt HO. High-dose soluble antigen: peripheral T-cell proliferation or apoptosis. Immunol Rev 1994; 142:193 - 208
   PubMed Web of Science ®Google Scholar
• Tisch R, McDevitt HO. Antigen-specific immunotherapy: is it a real possibility to combat T-cell-mediated autoimmunity?. Proc Natl Acad Sci USA 1994; 91:437 - 438
   PubMed Web of Science ®Google Scholar
• Harrison LC, Hafler DA. Antigen-specific therapy for autoimmune disease. Curr Opin Immunol 2000; 12:704 - 711
   PubMed Web of Science ®Google Scholar
• Fousteri G, Bresson D, von Herrath M. Rational development of antigen-specific therapies for type 1 diabetes. Adv Exp Med Biol 2007; 601:313 - 319
   PubMed Web of Science ®Google Scholar
• Luo X, Herold KC, Miller SD. Immunotherapy of Type 1 diabetes: Where are we and where should we be going?. Immunity 2010; 32:488 - 499
   PubMed Web of Science ®Google Scholar
• Wang B, Tisch R. Parameters influencing antigen-specific immunotherapy for Type 1 diabetes. Immunol Res 2008; 42:246 - 258
   PubMed Web of Science ®Google Scholar
• Staeva-Vieira T, Peakman M, von Herrath M. Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes. Clin Exp Immunol 2007; 148:17 - 31
   PubMed Web of Science ®Google Scholar
• Tian J, Kaufman DL. Antigen-based therapy for the treatment of type 1 diabetes. Diabetes 2009; 58:1939 - 1946
   PubMed Web of Science ®Google Scholar
• Rapoport MJ, Jaramillo A, Zipris D, Lazarus AH, Serreze DV, Leiter EH, et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993; 178:87 - 99
   PubMed Web of Science ®Google Scholar
• Pennline KJ, Roque-Gaffney E, Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 1994; 71:169 - 175
   PubMedGoogle Scholar
• Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, et al. Central role of defective interleukin-2 production in triggering islet autoimmune destruction. Immunity 2008; 28:687 - 697
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22:531 - 562
   PubMed Web of Science ®Google Scholar
• Haller MJ, Gottlieb PA, Schatz DA. Type 1 diabetes intervention trials 2007: where are we and where are we going?. Curr Opin Endocrinol Diabetes Obes 2007; 14:283 - 287
   PubMedGoogle Scholar
• Bougneres PF, Landais P, Boisson C, Carel JC, Frament N, Boitard C, et al. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 1990; 39:1264 - 1272
   PubMed Web of Science ®Google Scholar
• Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhi E, Kneteman NM, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54:2060 - 2069
   PubMed Web of Science ®Google Scholar
• Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med 1989; 320:550 - 554
   PubMed Web of Science ®Google Scholar
• Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J Immunol 2005; 175:633 - 639
   PubMed Web of Science ®Google Scholar
• Lu S, Wang S, Grimes-Serrano JM. Current Progress of DNA vaccine studies in humans. Expert Rev Vaccines 2008; 7:175 - 191
   PubMed Web of Science ®Google Scholar
• Garren H, Steinman L. Fathman CG. DNA vaccination in the treatment of autoimmune disease. Biologic and Gene Therapy of Autoimmune Disease 2000; Basel Karger 203 - 216
   Google Scholar
• Abdulhaqq SA, Weiner DB. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res 2008; 42:219 - 232
   PubMed Web of Science ®Google Scholar
• Williams JA, Carnes AE, Hodgson CP. Plasmid DNA vaccine vector design: Impact on efficacy, safety and upstream production. Biotech Adv 2009; 27:353 - 370
   PubMed Web of Science ®Google Scholar
• Feltquate DM, Heaney S, Webster RG, Robinson HL. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 1997; 158:2278 - 2284
   PubMed Web of Science ®Google Scholar
• Weiss R, Scheiblhofer S, Freund J, Ferreira F, Livey I, Thalhamer J. Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines. Vaccine 2002; 20:3148 - 3154
   PubMed Web of Science ®Google Scholar
• Goudy KS, Wang B, Tisch R. Gene gun-mediated DNA vaccination enhances antigen-specific immunotherapy at a late preclinical stage of type 1 diabetes on nonobese diabetic mice. Clin Immunol 2008; 129:49 - 57
   PubMed Web of Science ®Google Scholar
• Ewert KK, Ahmad A, Bouxsein NF, Evans HM, Safinya CR. Non-viral gene delivery with cationic liposome-DNA complexes. Methods Mol Biol 2008; 433:159 - 175
   PubMedGoogle Scholar
• Bodles-Brakhop AM, Heller R, Draghia-Akli R. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol Ther 2009; 17:585 - 592
   PubMed Web of Science ®Google Scholar
• Shigihara T, Shimada A, Oikawa Y, Yoneyama H, Kanazawa Y, Okubo Y, et al. CXCL10 DNA vaccination prevents spontaneous diabetes through enhanced β cell proliferation in NOD mice. J Immunol 2005; 175:8401 - 8408
   PubMed Web of Science ®Google Scholar
• Meagher C, Arreaza G, Peters A, Strathdee CA, Gilbert PA, Mi QS, et al. CCL4 protects from Type 1 diabetes by altering islet β cell-targeted inflammatory responses. Diabetes 2007; 56:809 - 817
   PubMed Web of Science ®Google Scholar
• Cameron MJ, Strathdee CA, Holmes KD, Arreaza GA, Dekaban GA, Delovitch TL. Biolistic-mediated interleukin 4 gene transfer prevents onset of Type 1 diabetes. Human Gene Ther 2000; 11:1647 - 1656
   PubMed Web of Science ®Google Scholar
• Nitta Y, Tashiro F, Tokui M, Shimada A, Takei I, Tabayashi K, et al. Systemic delivery of interleukin 10 by intramuscular injection of expression plasmid DNA prevents autoimmune diabetes in nonobese diabetic mice. Human Gene Ther 1998; 9:1701 - 1707
   PubMed Web of Science ®Google Scholar
• Tisch R, Wang B, Weaver DJ, Liu B, Bui T, Arthos J, Serreze DV. Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination. J Immunol 2001; 166:2122 - 2132
   PubMed Web of Science ®Google Scholar
• Seifarth C, Pop S, Liu B, Wong CP, Tisch R. More stringent conditions of plasmid DNA vaccination are required to protect grafted versus endogenous islets in nonobese diabetic mice. J Immunol 2003; 171:469 - 476
   PubMed Web of Science ®Google Scholar
• Pop SM, Wong CP, He Q, Wang Y, Wallet MA, Goudy KS, et al. The type and frequency of immunoregulatory CD4+ T-cells govern the efficacy of antigen-specific immunotherapy in nonobese diabetic mice. Diabetes 2007; 56:1395 - 1402
   PubMed Web of Science ®Google Scholar
• Piccirillo CA, Chang Y, Prud'homme GJ. TGFβ1 somatic gene therapy prevents autoimmune disease in nonobese diabetic mice. J Immunol 1998; 161:3950 - 3956
   PubMed Web of Science ®Google Scholar
• Prud'homme GJ, Chang Y. Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein. Gene Ther 1999; 6:771 - 777
   PubMed Web of Science ®Google Scholar
• Weaver DJ, Liu B, Tisch R. Plasmid DNAs encoding insulin and glutamic acid decarboxylase 65 have distinct effects on the progression of autoimmune diabetes in nonobese diabetic mice. J Immunol 2001; 167:586 - 592
   PubMed Web of Science ®Google Scholar
• Bot A, Smith D, Bot S, Hughes A, Wolfe T, Wang L, et al. Plasmid vaccination with insulin B chain prevents autoimmune diabetes in nonobese diabetic mice. J Immunol 2001; 167:2950 - 2955
   PubMed Web of Science ®Google Scholar
• Urbanek-Ruiz I, Ruiz PJ, Paragas V, Garren H, Steinman L, Fathman CG. Immunization with DNA encoding an immunodominant peptide of insulin prevents diabetes in NOD mice. Clin Immunol 2001; 100:164 - 171
   PubMed Web of Science ®Google Scholar
• Solvason N, Lou YP, Peters W, Evans E, Martinez J, Ramirez U, et al. Improved efficacy of a tolerizing DNA vaccine for reversal of hyperglycemia through enhancement of gene expression and localization to intracellular sites. J Immunol 2008; 181:8298 - 8307
   PubMed Web of Science ®Google Scholar
• Every AL, Kramer DR, Mannering SI, Lew AM, Harrison LC. Intranasal vaccination with proinsulin DNA induces regulatory CD4+ T cells that prevent experimental autoimmune diabetes. J Immunol 2006; 176:4608 - 4615
   PubMed Web of Science ®Google Scholar
• Quintana FJ, Rotem A, Carmi P, Cohen IR. Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: modulation of spontaneous 60 kDa heat shock protein autoimmunity. J Immunol 2000; 165:6148 - 6155
   PubMed Web of Science ®Google Scholar
• Glinka Y, De PR, Croze F, Prud'homme GJ. Regulatory cytokine production stimulated by DNA vaccination against an altered form of glutamic acid decarboxylase 65 in nonobese diabetic mice. J Mol Med 2003; 81:175 - 184
   PubMed Web of Science ®Google Scholar
• Filippova M, Liu J, Escher A. Effects of plasmid DNA injection on cyclophosphamide-accelerated diabetes in NOD mice. DNA Cell Biol 2001; 20:175 - 181
   PubMed Web of Science ®Google Scholar
• Wolfe T, Bot A, Hughes A, Mohrle U, Rodrigo E, Jaume JC, et al. Endogenous expression levels of autoantigens influence success or failure of DNA immunizations to prevent type 1 diabetes: addition of IL-4 increases safety. Eur J Immunol 2002; 32:113 - 121
   PubMed Web of Science ®Google Scholar
• Glinka Y, Chang Y, Prud'homme GJ. Protective regulatory T cell generation in autoimmune diabetes by DNA covaccination with islet antigens and selective CTLA-4 ligand. Mol Ther 2006; 578 - 587
   PubMed Web of Science ®Google Scholar
• Kaplan DH, Jenison MC, Saeland S, Shlomchik WD, Shlomchik MJ. Epidermal langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity 2005; 23:611 - 620
   PubMed Web of Science ®Google Scholar
• Li AF, Escher A. Intradermal or oral delivery of GADencoding genetic vaccines suppress type 1 diabetes. DNA Cell Biol 2003; 22:227 - 232
   PubMed Web of Science ®Google Scholar
• Gottlieb P, Colman PG, Kipnes M, Ratner R, Aroda V, Rendell M, et al. Interim results of a phase I/II clinical trial of a DNA plasmid vaccine (BHT-3021) for type 1 diabetes 69th Annual Meeting of the American Diabetes Association June 5–9; 2009 New Orleans LA
   Google Scholar
• Draper SJ, Heeney JL. Viruses as vaccine vectors for infectious diseases and cancer. Nature Rev 2010; 8:62 - 73
   Web of Science ®Google Scholar
• Lasaro MO, Ertl HCJ. New insights on adenovirus as vaccine vectors. Mol Ther 2009; 17:1333 - 1339
   PubMed Web of Science ®Google Scholar
• Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Micro Rev 2008; 21:583 - 593
   PubMed Web of Science ®Google Scholar
• Gray SJ, Samulski RJ. Optimizing gene delivery vectors for the treatment of heart disease. Expert Opin Biol Ther 2008; 8:911 - 922
   PubMed Web of Science ®Google Scholar
• Smith RH. Adeno-associated virus integration: virus versus vector. Gene Ther 2008; 15:817 - 822
   PubMed Web of Science ®Google Scholar
• Mueller C, Flotte TR. Clinical therapy using recombinant adeno-associated virus vectors. Gene Ther 2008; 15:858 - 863
   PubMed Web of Science ®Google Scholar
• Ferrari FK, Samulski T, Shenk T, Samulski RJ. Secondstrand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996; 70:3227 - 3234
   PubMed Web of Science ®Google Scholar
• Wang Z, Ma HI, Li J, Sun L, Zhang J, Xiao X. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 2003; 10:2105 - 2111
   PubMed Web of Science ®Google Scholar
• McCarty DM, Fu H, Monahan PE, Toulson CE, Naik P, Samulski RJ. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 2003; 10:2112 - 2118
   PubMed Web of Science ®Google Scholar
• McCarty DM. Self-complementary AAV vectors; advances and applications. Mol Ther 2008; 16:1648 - 1656
   PubMed Web of Science ®Google Scholar
• Han G, Li Y, Wang J, Wang R, Chen G, Song L, et al. Active tolerance induction and prevention of autoimmune diabetes by immunogene therapy using recombinant adenoassociated virus expressing glutamic acid decarboxylase 65 peptide GAD(500-585). J Immunol 2005; 174:4516 - 4524
   PubMed Web of Science ®Google Scholar
• Han G, Wang R, Chen G, Wang J, Xu R, Feng J, et al. Gene delivery GAD 500 autoantigen by AAV serotype 1 prevented diabetes in NOD mice: transduction efficiency do not play important roles. Immunol Lett 2008; 115:110 - 116
   PubMed Web of Science ®Google Scholar
• Jindal RM, Karanam M, Shah R. Prevention of diabetes in the NOD mouse by intra-muscular injection of recombinant adeno-associated virus containing the preproinsulin II gene. Int J Exp Diabetes Res 2001; 2:129 - 138
   PubMedGoogle Scholar
• Goudy K, Song S, Wasserfall C, Zhang YC, Kapturczak M, Muir A, et al. Adeno-associated virus vector-mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice. Proc Natl Acad Sci USA 2001; 98:13913 - 13918
   PubMed Web of Science ®Google Scholar
• Goudy KS, Burkhardt BR, Wasserfall C, Song S, Campbell-Thompson ML, Brusko T, et al. Systemic overexpression of IL-10 induces CD4+CD25+ cell populations in vivo and ameliorates type 1 diabetes in nonobese diabetic mice in a dose-dependent fashion. J Immunol 2003; 171:2270 - 2278
   PubMed Web of Science ®Google Scholar
• Yang Z, Chen M, Wu R, Fialkow LB, Bromberg JS, McDuffie M, et al. Suppression of autoimmune diabetes by viral IL-10 gene transfer. J Immunol 2002; 168:6479 - 6485
   PubMed Web of Science ®Google Scholar
• Zhang YC, Pileggi A, Agarwal A, Molano RD, Powers M, Brusko T, et al. Adeno-associated virus-mediated IL-10 gene therapy inhibits diabetes recurrence in syngeneic islet cell transplantation of NOD mice. Diabetes 2003; 52:708 - 716
   PubMed Web of Science ®Google Scholar
• Song S, Goudy K, Campbell-Thompson M, Wasserfall C, Scott-Jorgensen M, Wang J, et al. Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice. Gene Ther 2004; 11:181 - 186
   PubMed Web of Science ®Google Scholar
• Hu CM, Lin HH, Chiang MT, Chang PF, Chau LY. Systemic expression of heme oxygenase-1 ameliorates type 1 diabetes in NOD mice. Diabetes 2007; 56:1240 - 1247
   PubMed Web of Science ®Google Scholar
• Grimstein C, Choi YK, Satoh M, Lu Y, Wang X, Campbell-Thompson M, et al. Combination of alpha-1 antitrypsin and doxycycline suppresses collagen-induced arthritis. J Gene Med 2010; 12:35 - 44
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhu T, Rehman KK, Bertera S, Zhang J, Chen C, et al. Widespread and stable pancreatic gene transfer by adeno-associated virus vectors via different routes. Diabetes 2006; 55:875 - 884
   PubMed Web of Science ®Google Scholar
• Flotte T, Agarwal A, Wang J, Song S, Fenjves ES, Inverardi L, et al. Efficient ex vivo transduction of pancreatic islet cells with recombinant adeno-associated virus vectors. Diabetes 2001; 50:515 - 520
   PubMed Web of Science ®Google Scholar
• Kapturczak M, Zolotukhin S, Cross J, Pileggi A, Molano RD, Jorgensen M, et al. Transduction of human and mouse pancreatic islet cells using a bicistronic recombinant adeno-associated viral vector. Mol Ther 2002; 5:154 - 160
   PubMed Web of Science ®Google Scholar
• Prasad KM, Yang Z, Bleich D, Nadler JL. Adeno-associated virus vector mediated gene transfer to pancreatic beta cells. Gene Ther 2000; 7:1553 - 1561
   PubMed Web of Science ®Google Scholar
• Rehman KK, Wang Z, Bottino R, Balamurugan AN, Trucco M, Li J, et al. Efficient gene delivery to human and rodent islets with double-stranded (ds) AAV-based vectors. Gene Ther 2005; 12:1313 - 1323
   PubMed Web of Science ®Google Scholar
• Michelfelder S, Kohlschutter J, Skorupa A, Pfennings S, Muller O, Kleinschmidt JA, et al. Successful expansion but not complete restriction of tropism of adeno-associated virus by in vivo biopanning of random virus display peptide libraries. PLoS One 2009; 4:5122
   PubMed Web of Science ®Google Scholar
• Muller OJ, Kaul F, Weitzman MD, Pasqualini R, Arap W, Kleinschmidt JA, et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol 2003; 21:1040 - 1046
   PubMed Web of Science ®Google Scholar
• Work LM, Buning H, Hunt E, Nicklin SA, Denby L, Britton N, et al. Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses. Mol Ther 2006; 13:683 - 693
   PubMed Web of Science ®Google Scholar
• Dodiya HB, Bjorklund T, Stansell J 3rd, Mandel RJ, Kirik D, Kordower JH. Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther 2010; 18:579 - 587
   PubMed Web of Science ®Google Scholar
• Grimm D, Zhou S, Nakai H, Thomas CE, Storm TA, Fuess S, et al. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 2003; 102:2412 - 2419
   PubMed Web of Science ®Google Scholar
• Rebuffat A, Harding CO, Ding Z, Thony B. Comparison of adeno-associated virus pseudotype 1, 2 and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuria. Hum Gene Ther 2010; 21:463 - 477
   PubMed Web of Science ®Google Scholar
• Rehman KK, Trucco M, Wang Z, Xiao X, Robbins PD. AAV8-mediated gene transfer of interleukin-4 to endogenous beta-cells prevents the onset of diabetes in NOD mice. Mol Ther 2008; 16:1409 - 1416
   PubMed Web of Science ®Google Scholar
• Riedel MJ, Gaddy DF, Asadi A, Robbins PD, Kieffer TJ. DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells ameliorates streptozotocin-induced diabetes. Gene Ther 2010; 17:171 - 180
   PubMed Web of Science ®Google Scholar
• Giannoukakis N, Trucco M. Gene therapy for type 1 diabetes. Am J Ther 2005; 12:512 - 528
   PubMed Web of Science ®Google Scholar
• Crooke ST. Progress in antisense technology. Annu Rev Med 2004; 55:61 - 95
   PubMed Web of Science ®Google Scholar
• Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol 2010; 50:259 - 293
   Google Scholar
• Machen J, Harnaha J, Lakomy R, Styche A, Trucco M, Giannoukakis N. Antisense oligonucleotides downregulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J Immunol 2004; 173:4331 - 4341
   PubMed Web of Science ®Google Scholar
• Phillips B, Nylander K, Harnaha J, Machen J, Lakomy R, Styche A, et al. A microsphere-based vaccine prevents and reverses new-onset autoimmune diabetes. Diabetes 2008; 57:1544 - 1555
   PubMed Web of Science ®Google Scholar
• Garren H. A DNA vaccine for multiple sclerosis. Expert Opin Biol Ther 2008; 8:1539 - 1549
   PubMed Web of Science ®Google Scholar
• Ranasinghe C, Ramshaw IA. Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity. Expert Rev Vaccines 2009; 8:1171 - 1181
   PubMed Web of Science ®Google Scholar
• Bresson D, Fradkin M, Manenkova Y, Rottembourg D, von Herrath M. Genetic-induced variations in the GAD65 T cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes. Mol Ther 2010; 18:307 - 316
   PubMed Web of Science ®Google Scholar
• Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003; 9:1202 - 1208
   PubMed Web of Science ®Google Scholar
• Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997; 158:2947 - 2954
   PubMed Web of Science ®Google Scholar
• Ko KS, Lee M, Koh JJ, Kim SW. Combined administration of plasmids encoding IL-4 and IL-10 prevents the development of autoimmune diabetes in nonobese diabetic miice. Mol Ther 2001; 4:313 - 316
   PubMed Web of Science ®Google Scholar
• Balasa B, Boehm BO, Fortnagel A, Karges W, Van Gunst K, Jung N, et al. Vaccination with glutamic acid decarboxylase plasmid DNA protects mice from spontaneous autoimmune diabetes and B7/CD28 costimulation circumvents that protection. Clin Immunol 2001; 99:241 - 252
   PubMed Web of Science ®Google Scholar
• Glinka Y, Pooter R, Croze F, Prud'homme GJ. Regulatory cytokine production stimulated by DNA vaccination against an altered form of glutamic acid decarboxylase 65 in nonobese diabetic mice. J Mol Med 2003; 81:175 - 184
   PubMed Web of Science ®Google Scholar
• Prud'homme GJ, Chang Y, Li X. Immunoinhibitory DNA vaccine protects against autoimmune diabetes through cDNA encoding a selective CTLA-4 (CD152) ligand. Human Gene Ther 2002; 13:395 - 406
   PubMed Web of Science ®Google Scholar
• Li A, Ojogho O, Franco E, Baron P, Iwaki Y, Escher A. Pro-apoptotic DNA vaccination ameliorates new onset of autoimmune diabetes in NOD mice and induces foxp3+ regulatory T cells in vitro. Vaccine 2006; 24:5036 - 5046
   PubMed Web of Science ®Google Scholar
• Yamada K, Moriyama H, Okumachi Y, Arai T, Kameno M, Kishi M, et al. Intravenous administration of proinsulin 1 or 2-expressing fiber-mutant recombinant adenovirus vector protects against the development of diabetes in NOD mice. Ann NY Acad Sci 2008; 1150:183 - 186
   PubMed Web of Science ®Google Scholar
• Fernandes JR, Duvivier-Kali VF, Keegan M, Hollister-Lock J, Omer A, Su S, et al. Transplantation of islets transduced with CTLA4-Ig and TGFbeta using adenovirus and lentivirus vectors. Transpl Immunol 2004; 13:191 - 200
   PubMed Web of Science ®Google Scholar
• Park L, Lee E, Lee S, Lim M, Hong H, Shin G, et al. TGFbeta plasmid construction and delivery for the prevention of type 1 diabetes. Ann N Y Acad Sci 2008; 1150:177 - 182
   PubMed Web of Science ®Google Scholar
• Luo X, Yang H, Kim IS, Saint-Hillaire F, Thomas DA, De BP, et al. Systemic transforming growth factor-beta1 gene therapy induced FoxP3+ regulatory cells, restores self-tolerance, and facilitates regeneration of beta cell function in overtly diabetic nonobese diabetic mice. Transplantation 2005; 79:1091 - 1096
   PubMed Web of Science ®Google Scholar
• Sakata M, Yasuda H, Moriyama H, Yamada K, Kotani R, Kurohara M, et al. Prevention of recurrent but not spontaneous autoimmune diabetes by transplanted NOD islets adenovirally transduced with immunomodulating molecules. Diabetes Res Clin Pract 2008; 80:352 - 359
   PubMed Web of Science ®Google Scholar
• Yasuda H, Nagata M, Arisawa K, Yoshida R, Fujihira K, Okamoto N, et al. Local expression of immunoregulatory IL-12p40 gene prolonged syngeneic islet graft survival in diabetic NOD mice. J Clin Invest 1998; 102:1807 - 1814
   PubMed Web of Science ®Google Scholar
• Smith DK, Korbutt GS, Suarez-Pinzon WL, Kao D, Rajotte RV, Elliott JF. Interleukin-4 or interleukin-10 expressed from adenovirus-transduced syngeneic islet grafts fails to prevent beta cell destruction in diabetic NOD mice. Transplantation 1997; 64:1040 - 1049
   PubMed Web of Science ®Google Scholar
• Cameron MJ, Arreaza GA, Waldhauser L, Gauldie J, Delovitch TL. Immunotherapy of spontaneous type 1 diabetes in nonobese diabetic mice by systemic interleukin-4 treatment employing adenovirus vector-mediated gene transfer. Gene Ther 2000; 7:1840 - 1846
   PubMed Web of Science ®Google Scholar
• Alexander AM, Crawford M, Bertera S, Rudert WA, Takikawa O, Robbins PD, et al. Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes 2002; 51:356 - 365
   PubMed Web of Science ®Google Scholar
• Panakanti R, Mahato RI. Bipartite vector encoding hVEGF and hIL-1Ra for ex vivo transduction into human islets. Mol Pharm 2009; 6:274 - 284
   PubMed Web of Science ®Google Scholar
• Panakanti R, Mahato RI. Bipartite adenoviral vector encoding hHGF and hIL-1Ra for improved human islet transplantation. Pharm Res 2009; 26:587 - 596
   PubMed Web of Science ®Google Scholar
• Narang AS, Sabek O, Gaber AO, Mahato RI. Co-expression of vascular endothelial growth factor and interleukin-1 receptor antagonist improves human islet survival and function 2006; 23:1970 - 1982
   Google Scholar
• Kawamoto K, Tanemura M, Komoda H, Omori T, Fumimoto Y, Shimada K, et al. Adenoviral-mediated overexpression of membrane-bound human FasL and human decoy Fas protect pig islets against human CD8+ CTL-mediated cytotoxicity. Transplant Proc 2006; 38:3286 - 3288
   PubMed Web of Science ®Google Scholar
• Kawamoto K, Tanemura M, Saga A, Komoda H, Fumimoto Y, Deguchi T, et al. Adenoviral-mediated overexpression of either membrane-bound human FasL or human decoy Fas can prolong pig islet xenograft survival in a rat transplant model. Transplant Proc 2008; 40:477 - 479
   PubMed Web of Science ®Google Scholar
• Giannoukakis N, Mi Z, Rudert WA, Gambotto A, Trucco M, Robbins P. Prevention of beta cell dysfunction and apoptosis activation in human islets by adenoviral gene transfer of the insulin-like growth factor I. Gene Ther 2000; 7:2015 - 2022
   PubMed Web of Science ®Google Scholar
• Zhang YC, Molano RD, Pileggi A, Powers M, Cross J, Wasserfall C, et al. Adeno-associated virus transduction of islets with interleukin-4 results in impaired metabolic function in syngeneic marginal islet mass transplantation. Transplantation 2002; 74:1184 - 1186
   PubMed Web of Science ®Google Scholar
• Zhang YC, Pileggi A, Molano RD, Wasserfall C, Campbell-Thompson M, Ricordi C, et al. Systemic overexpression of interleukin-10 fails to protect allogeneic islet transplants in nonobese diabetic mice. Transplantation 2005; 80:530 - 533
   PubMed Web of Science ®Google Scholar
• Carter JD, Ellett JD, Chen M, Smith KM, Fialkow LB, McDuffie MJ, et al. Viral IL-10-mediated immune regulation in pancreatic islet transplantation. Mol Ther 2005; 12:360 - 368
   PubMed Web of Science ®Google Scholar
• Oh TK, Li MZ, Kim ST. Gene therapy for diabetes mellitus in rats by intramuscular injection of lentivirus containing insulin gene. Diabetes Res Clin Pract 2006; 71:233 - 240
   PubMed Web of Science ®Google Scholar
• Gallichan WS, Kafri T, Krahl T, Verma IM, Sarvetnick N. Lentivirus-mediated transduction of islet grafts with interleukin 4 results in sustained gene expression and protection from insulitis. Hum Gene Ther 1998; 18:2717 - 2726
   Web of Science ®Google Scholar
• Chou FC, Sytwu HK. Overexpression of thioredoxin in islets transduced by a lentiviral vector prolongs graft survival in autoimmune diabetic NOD mice. J Biomed Sci 2009; 16:71
   PubMed Web of Science ®Google Scholar
• Giannoukakis N, Mi Z, Gambotto A, Eramo A, Ricordi C, Trucco M, et al. Infection of intact human islets by a lentiviral vector. Gene Ther 1999; 6:1545 - 1551
   PubMed Web of Science ®Google Scholar
• Fenjves ES, Ochoa MS, Cechin S, Gay-Rabinstein C, Pérez-Alvarez I, Ichii H, et al. Protection of human pancreatic islets using a lentiviral vector expressing two genes: cFLIP and GFP. Cell Transplant 2008; 17:793 - 802
   PubMed Web of Science ®Google Scholar